Oxford Asset Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-23,084
| Closed | -$417K | – | 2274 |
|
|
2018
Q3 | $417K | Sell |
23,084
-19,737
| -46% | -$339K | 0.01% | 1383 |
|
|
2018
Q2 | $594K | Sell |
42,821
-121,145
| -74% | -$1.44M | 0.01% | 1274 |
|
|
2018
Q1 | $1.49M | Buy |
163,966
+74,199
| +83% | +$409K | 0.03% | 735 |
|
|
2017
Q4 | $395K | Buy |
+89,767
| New | +$428K | 0.01% | 1257 |
|
|
2017
Q3 | – | Sell |
-29,927
| Closed | -$45K | – | 1815 |
|
|
2017
Q2 | $45K | Sell |
29,927
-90,632
| -75% | -$195K | ﹤0.01% | 1431 |
|
|
2017
Q1 | $310K | Sell |
120,559
-88,701
| -42% | -$205K | 0.01% | 1188 |
|
|
2016
Q4 | $534K | Buy |
209,260
+55,175
| +36% | +$158K | 0.02% | 578 |
|
|
2016
Q3 | $476K | Sell |
154,085
-44,928
| -23% | -$140K | 0.01% | 623 |
|
|
2016
Q2 | $639K | Sell |
199,013
-45,179
| -19% | -$166K | 0.02% | 559 |
|
|
2016
Q1 | $757K | Buy |
244,192
+181,620
| +290% | +$593K | 0.02% | 534 |
|
|
2015
Q4 | $253K | Sell |
62,572
-13,453
| -18% | -$62K | 0.01% | 771 |
|
|
2015
Q3 | $348K | Sell |
76,025
-170,386
| -69% | -$892K | 0.01% | 537 |
|
|
2015
Q2 | $1.28M | Buy |
246,411
+18,036
| +8% | +$108K | 0.03% | 416 |
|
|
2015
Q1 | $1.43M | Buy |
+228,375
| New | +$1.32M | 0.04% | 407 |
|
|
2014
Q2 | – | Sell |
-239,007
| Closed | -$5.69M | – | 831 |
|
|
2014
Q1 | $5.69M | Buy |
+239,007
| New | +$3.47M | 0.17% | 197 |
|
|
2013
Q4 | – | Sell |
-50,108
| Closed | -$668K | – | 850 |
|
|
2013
Q3 | $668K | Sell |
50,108
-7,986
| -14% | -$126K | 0.01% | 624 |
|
|
2013
Q2 | $763K | Buy |
+58,094
| New | +$783K | 0.02% | 629 |
|
Other funds holding ECYT
Oxford Asset Management's ECYT Position: Q4 2018 in Review
Oxford Asset Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 23,084 shares — an estimated $417K sold.
Oxford Asset Management first reported a position in ECYT in Q2 2013 and held it in 17 quarters. The position peaked at $5.69M in Q1 2014. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.
- Oxford Asset Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
- Oxford Asset Management sold 23,084 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $417K.
- Oxford Asset Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 17 quarters.
- Oxford Asset Management's Endocyte, Inc. Common Stock position peaked at $5.69M in Q1 2014.
- 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.
Based on Oxford Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.